Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain
Shots:
- The P-IIb trial is evaluating XG005 (1250mg or 750mg, BID, oral) vs PBO in patients (n=450) for managing acute pain after bunionectomy
- Results showed reduced pain intensity over 72hrs. post-surgery, with mild pain (<4 NRS) in high dose group vs severe pain (>7 NRS) in PBO; delayed rescue medication use of up to 8-fold in high dose group [medians: 31.47 (high dose) & 12.24 (low dose) vs 4.03hrs.)] & lower opioid use in both arms, with Morphine Equivalent Doses of 6.72mg (high dose) & 9.38mg (low dose) vs 23.86/24.68mg
- XG005 significantly reduced acetaminophen use [means: 1586.03mg (high dose) & 1975.89mg (low dose) vs 4812.7mg) over 72hrs. plus improved Patient Global Assessment (PGA) scores & sleep quality
Ref: Businesswire | Image: Xgene Pharmaceutical
Related News:- ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
